UK accepts J&J's money-back guarantee

It's official: the UK's National Health Service will start using Johnson & Johnson's Velcade, under an unprecedented money-back-guarantee program. Patients who respond to the drug will be fully funded. Patients who respond only minimally or not all all will be taken off Velcade, and J&J will refund the cost to NHS. The guarantee was the only way J&J could persuade the National Institute for Clinical Excellence--the drug gatekeepers for NHS--to reimburse for the drug at all.

- check out the CNN Money report
- read an analysis of the deal in The Telegraph

Related Articles:
J&J drug gets money-back guarantee. Report
Positive Velcade data fuels stock rise. Report
NHS fights expensive Alzheimer's drugs. Report
Metric: Biotech drugs fueling costs. Report

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.